Table 1 Patients’ clinicopathological and hematological characteristics

Sex

 Female

 Male

34(30.1%)

79(69.9%)

30(27.0%)

81(73.0%)

8(20.0%)

32(80.0%)

13(34.2%)

25(65.8%)

Age (years)

 < 60

 ≥ 60

48(42.5%)

65(57.5%)

58(52.3%)

53(47.7%)

19(47.5%)

21(52.5%)

14(36.8%)

24(63.2%)

Lauren type

 Intestinal

 Diffuse

 Mixed

 Unknown

48(42.5%)

31(27.4%)

23(20.4%)

11(9.7%)

41(36.9%)

31(27.9%)

27(24.3%)

12(10.8%)

7(17.5%)

11(27.5%)

4(10.0%)

18(45.0%)

9(23.7%)

9(23.7%)

7(18.4%)

13(34.2%)

Primary tumor site

 Upper third

 Middle third

 Lower third

61(54.0%)

22(19.5%)

30(26.5%)

53(47.7%)

33(29.7%)

25(22.5%)

17(42.5%)

8(20.0%)

15(37.5%)

25(65.8%)

4(10.5%)

9(23.7%)

WHO histological grade

 Low

 Moderate/ High

 Unknown

57(50.4%)

56(49.6%)

0(0%)

55(49.5%)

52(46.8%)

4(3.7%)

21(52.5%)

13(32.5%)

6(15.0%)

20(52.6%)

12(31.6%)

6(15.8%)

cTNM stage

 III

 IV

96(85.0%)

17(15.0%)

97(87.4%)

14(12.6%)

39(97.5%)

1(2.5%)

33(86.8%)

5(13.2%)

Hematological toxicity

 Grade 3 + Leukopenia

 Grade 3 + Neutropenia

 Grade 3 + Anemia

 Grade 3 + thrombocytopenia

 Grade 3 + Total HTs

13(11.5%)

12(10.6%)

16(14.2%)

13(11.5%)

31(27.4%)

1(0.9%)

5(4.5%)

16(14.4%)

0(0%)

18(16.2%)

6(15.0%)

6(15.0%)

7(17.5%)

4(10.0%)

14(35.0%)

0(0%)

1(2.6%)

4(10.5%)

0(0%)

5(13.2%)

Blood cell nadir value

 WBC (10^9/L)

 ANC (10^9/L)

 HGB (g/L)

 PLT (10^9/L)

3.05±0.91

1.82±0.68

98.69±16.94

97.08±43.22

4.83±1.67

2.60±1.43

105.96±22.83

156.94±51.88

3.27±1.23

1.98±0.88

101.98±20.59

122.1±65.47

4.65±1.22

2.28±0.79

114.68±20.05

158.66±37.70

Pre-WBC (10^9/L)

6.20(5.15–7.37)

6.34(5.14–7.80)

6.67(5.49–8.14)

6.03(4.80–7.74)

Pre-ANC (10^9/L)

4.00(3.00-4.90)

3.81(3.00-5.20)

3.71(2.91–4.68)

3.57(2.59–4.60)

Pre-HGB (g/L)

122(100–136)

125(104–139)

130(108–143)

130(119–139)

Pre-PLT (10^9/L)

286(219–337)

292(230–372)

283(243–338)

268(236–321)